Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation.
Bone loss, a recognized complication of renal transplantation (TP), is mainly attributed to steroids. The effect of other immunosuppressive agents on patients' bone mass is difficult to distinguish from that of steroids. In this study, we evaluate the evolution of bone mass density over the first 12 months following renal TP in two groups of patients given either low-dose steroids with tacrolimus ( n=7) or normal-dose steroids and cyclosporine ( n=19). Bone mineral density (BMD) of the lumbar spine, total hip, and hip subregions and total-body bone mineral content (BMC) were measured by dual-energy X-ray absorptiometry within the first 15 days, and 1 year after TP. Biological markers of bone turnover (serum calcium, phosphate, total alkaline phosphatase activity, intact parathyroid hormone, bone-specific alkaline phosphatase, calcitriol, and urinary pyridinolines) were regularly measured during follow-up. After TP, renal function improved rapidly in all patients. One year after TP, bone mass had decreased significantly in the cyclosporine group in all investigated sites. By contrast it had increased in the tacrolimus group. In order to compare the evolution of bone mass in patients given similar amounts of steroids, the cyclosporine group was subdivided in tertiles according to the 1-year cumulative oral intake of prednisolone. A significant bone loss was still observed in the low-steroid cyclosporine subgroup but not in the tacrolimus group, despite the similar steroids intake (3.5+/-0.5 g and 2.7+/-1 g, respectively). Bone gain in the tacrolimus group occurred despite a previous longer dialysis duration and a higher number of postmenopausal women who were not receiving hormone substitutes. Long-term evaluation of bone density (3-5 years post-TP) confirmed the bone gain in the tacrolimus patients. Interestingly, the profile of the biological markers of bone turnover appeared better in patients prescribed tacrolimus than in those given cyclosporine, though the differences did not reach statistical significance. Weconclude that tacrolimus associated with low-dose steroids might better preserve bone mass after renal TP than cyclosporine and normal doses of steroids.
Goffin
Eric
E
Department of Nephrology, Hopital Saint-Luc, Université Catholique de Louvain, 10 Ave. Hippocrate, 1200 Brussels, Belgium. goffin@nefr.ucl.ac.be
Devogelaer
Jean-Pierre
JP
Lalaoui
Abdelhamid
A
Depresseux
Geneviève
G
De Naeyer
Philippe
P
Squifflet
Jean-Paul
JP
Pirson
Yves
Y
van Ypersele de Strihou
Charles
C
D015502:Absorptiometry, Photon; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D007166:Immunosuppressive Agents; D010710:Phosphates; D016572:Cyclosporine; D003404:Creatinine; D002118:Calcium; D016559:Tacrolimus